Clinical Trial: Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA >= 0.2 ng/mL (EvoPAR-PR05)

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07711002) titled 'Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA >= 0.2 ng/mL (EvoPAR-PR05)' on July 14.

Brief Summary: The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA >= 0.2 ng/mL.

Study Start Da...